What you need to know:
– COTA, a leading real-world data (RWD) and analytics company in oncology, announces a new partnership with Sanofi.
– This strategic partnership aims to leverage RWD and artificial intelligence (AI) to accelerate clinical trials specifically focused on multiple myeloma, a cancer that affects white blood cells. The findings from this partnership could have a major impact on future clinical trial design in multiple myeloma.
Draw insights from real-world data
COTA's RWD analysis expertise will assist in this effort. Their comprehensive dataset provides valuable insight into real-world treatment pathways for cancer patients. This data provides Sanofi with critical information about key patient populations battling multiple myeloma.
Focus on multiple myeloma
The first project will revolve around multiple myeloma, a complex blood cancer. By analyzing RWD, the collaborators aim to:
- Clarify the treatment situation: Gain a clearer understanding of evolving treatment options for multiple myeloma.
- Notify me of upcoming trials: Insights gleaned from RWD analysis will be used to design more efficient and targeted clinical studies in the future.
- Interpret ongoing clinical trials: RWD can provide a valuable context for interpreting the results of ongoing and future multiple myeloma trials, ensuring relevance to real-world treatment practice.
Guide trial interpreter
Additionally, insights from collaborative research will help interpret the results of current and future clinical trials. Understanding how new treatments compare to existing standard treatments for patients with multiple myeloma can help researchers make more informed decisions about treatment possibilities .
“Our collaboration with Sanofi has the potential to help more patients and their families benefit from breakthrough treatments in the short term,” said CK Wang, medical oncologist and chief medical officer at COTA. the doctor said. “We are delivering high-quality RWD enabled by new AI-based tools to accelerate drug research and improve patient care.”